<unk> , sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses").
Olaratumab
Ustekinumab
Emapalumab
Evolocumab
Evinacumab
Dupilumab
Anifrolumab
Alirocumab